GET DAILY SIGNALSOvid Therapeutics (OVID): A Closer Look at This Clinical-Stage Biotech's Pipeline
Key Takeaways
- OVID is Ovid Therapeutics Inc., a clinical-stage biopharmaceutical company focused on small-molecule medicines for neurological and neuropsychiatric disorders, particularly rare epilepsies and seizure-related conditions.
- Founded in 2014 and headquartered in New York City, the company completed its initial public offering (IPO) on the Nasdaq in May 2017.
- Its pipeline centers on OV329, a GABA-aminotransferase (GABA-AT) inhibitor, and OV4071, a KCC2 transporter activator.
- Ovid has historically generated most of its revenue through licensing and collaboration arrangements, notably with Takeda Pharmaceutical Company Limited, rather than from product sales.
- As an early-stage biotech, the company has reported recurring net losses and relies on raising capital and partnerships to fund research and development (R&D).
Background on Ovid Therapeutics
Ovid Therapeutics Inc. (OVID) is a biopharmaceutical company dedicated to developing better, gentler medicines for the brain. The company focuses on rare epilepsies and seizure-related neurological disorders, along with certain neuropsychiatric conditions, where patients often have limited treatment options. Investors follow OVID primarily for its drug pipeline and the potential value of its clinical-stage programs rather than for current sales, making it a classic development-stage biotechnology story. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Company Profile and Business Model
Ovid Therapeutics was founded on April 1, 2014, by Matthew During and Jeremy M. Levin, and is incorporated in Delaware with its principal executive office in New York City. The company listed its shares on the Nasdaq stock market through an IPO in May 2017. It is a small organization, reporting roughly two dozen employees.
Ovid's business model is built around discovering and developing novel small-molecule drug candidates, advancing them through clinical trials, and then partnering with or licensing them to larger pharmaceutical companies. The company does not currently rely on commercial product sales. Historically, its primary revenue source has been a royalty, license, and termination agreement with Takeda Pharmaceutical Company Limited, related to the epilepsy drug candidate soticlestat.
Pipeline and Key Programs
The company's lead development programs include OV329, a next-generation GABA-aminotransferase (GABA-AT) inhibitor being studied for treatment-resistant focal onset seizures, tuberous sclerosis complex (TSC)-associated seizures, and infantile spasms. OV4071 is a potassium-chloride cotransporter 2 (KCC2) direct activator being investigated for conditions including psychosis associated with Parkinson's disease, Lewy body dementia, and acute schizophrenia.
Ovid has also maintained license and collaboration agreements with entities such as AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc., reflecting its strategy of leveraging external partnerships and intellectual property.
Why This Stock Draws Investor Attention
Investors track OVID because it operates in the high-need field of rare neurological and seizure disorders, where successful therapies can address significant unmet medical demand. Its pipeline targets novel mechanisms of action, which, if validated in clinical trials, could differentiate its drug candidates from existing treatments. The company's market position rests on its specialized focus on epilepsy and brain disorders and its ability to monetize programs through partnerships and milestone-based licensing deals rather than through a large commercial infrastructure.
For a development-stage biotech, the financial profile is defined less by current revenue and more by cash position, R&D spending, and the progress of clinical milestones. Investors therefore follow data readouts, regulatory designations, and partnership developments as signals of the company's long-term potential.
Risks and Key Considerations
Investing in OVID carries risks common to early-stage biotechnology companies. The company has reported recurring net losses and negative operating cash flow since inception and expects losses to continue. Its ability to fund operations depends on raising additional capital through equity offerings, debt, or collaborations, which may dilute existing shareholders or not be available on favorable terms.
Other key considerations include the inherent uncertainty of clinical trials, which may fail or be delayed; reliance on third parties for manufacturing and collaborations; competition from larger pharmaceutical companies; and regulatory hurdles required for drug approval. As with many small biotechs, the company's future is highly dependent on the success of a limited number of drug candidates.
Integrating AI Tools Into Biotech Research
In my view, tools like Tickeron's AI Screener help streamline the process of comparing development-stage names like OVID against peers by filtering on fundamentals, volatility, and industry patterns. This approach has become a regular part of how I evaluate early-stage opportunities without adding unnecessary steps to the workflow.
Conclusion
Ovid Therapeutics occupies a specialized position in the biotechnology landscape, concentrating on rare epilepsies and seizure-related neurological disorders through a focused pipeline of small-molecule candidates. Its partnership-driven business model, coupled with programs targeting novel mechanisms of action, distinguishes it from larger, commercially diversified pharmaceutical firms. For investors, OVID represents a high-risk, high-uncertainty development-stage opportunity whose value is tied primarily to clinical progress and its ability to secure funding and collaborations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
OVID's RSI Oscillator recovers from oversold territory
The RSI Indicator for OVID moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 25 similar instances when the indicator left oversold territory. In 23 of the 25 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for OVID just turned positive on October 21, 2026. Looking at past instances where OVID's MACD turned positive, the stock continued to rise in 45 of 52 cases over the following month. The odds of a continued upward trend are 87%.
OVID moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for OVID crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.
Following a +14.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where OVID advanced for three days, in 207 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 158 of 189 cases where OVID Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 52 of 57 cases where OVID's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OVID as a result. In 83 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OVID declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
OVID broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.652) is normal, around the industry mean (3.498). P/E Ratio (-13.571) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (204.082) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. OVID’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OVID’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Provides medicines to children and adults with neurological disorders
Industry Biotechnology
Advertisement